CRISPR THERAPEUTICS AG Increase (Decrease) in Restricted Cash
CRISPR THERAPEUTICS AG (CRSP) reported Increase (Decrease) in Restricted Cash of $4.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2018-03-08
- CRISPR THERAPEUTICS AG increase (decrease) in restricted cash for the quarter ending 2017-12-31 was $0.00.
- CRISPR THERAPEUTICS AG increase (decrease) in restricted cash for the quarter ending 2017-09-30 was $0.00.
- CRISPR THERAPEUTICS AG increase (decrease) in restricted cash for the quarter ending 2017-06-30 was $3.00K, a 99.88% decline year-over-year.
- CRISPR THERAPEUTICS AG increase (decrease) in restricted cash for the quarter ending 2017-03-31 was $1.00K, a 50.00% decline year-over-year.
- CRISPR THERAPEUTICS AG increase (decrease) in restricted cash for fiscal 2017 was $4.00K, a 99.84% decline from fiscal 2016.
- CRISPR THERAPEUTICS AG increase (decrease) in restricted cash for fiscal 2016 was $2.45M, a 276.92% increase from fiscal 2015.
- CRISPR THERAPEUTICS AG increase (decrease) in restricted cash for fiscal 2015 was $650.00K, a 3962.50% increase from fiscal 2014.
- CRISPR THERAPEUTICS AG increase (decrease) in restricted cash for fiscal 2014 was $16.00K.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 6 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $0.00 derived: sum of 2 quarters · filed 2018-03-08 | $3.00K derived: sum of 3 quarters · filed 2018-03-08 | $4.00K 10-K · filed 2018-03-08 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $3.00K derived: sum of 2 quarters · filed 2017-11-08 | $4.00K 10-Q · filed 2017-11-08 | $1.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $4.00K 10-Q · filed 2017-08-10 | $1.00K derived: sum of 3 quarters · filed 2018-03-08 | $1.00K derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-03-31 | $1.00K 10-Q · filed 2017-05-11 | -$2.00K derived: sum of 2 quarters · filed 2018-03-08 | -$2.00K derived: sum of 3 quarters · filed 2018-03-08 | $2.45M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$3.00K derived: sum of 2 quarters · filed 2018-03-08 | $2.45M derived: sum of 3 quarters · filed 2018-03-08 | $2.45M 10-K · filed 2018-03-08 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.45M derived: sum of 2 quarters · filed 2017-11-08 | $2.45M 10-Q · filed 2017-11-08 | $2.55M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $2.45M 10-Q · filed 2017-08-10 | $2.55M derived: sum of 3 quarters · filed 2018-03-08 | |
| 2016-03-31 | $2.00K 10-Q · filed 2017-05-11 | $101.00K derived: sum of 2 quarters · filed 2018-03-08 | ||
| 2015-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $650.00K 10-K · filed 2018-03-08 | ||
| 2015-09-30 | $551.00K 10-Q · filed 2016-11-22 | |||
| 2014-12-31 | $16.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |